Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology

Human Gene Therapy

Volumn 21, Issue 11, 2010, Pages 1569-1576

  Movsesyan, Nina ^a,b   Davtyan, Hayk ^a   Mkrtichyan, Mikayel ^a   Petrushina, Irina ^b   Tiraturyan, Tigran ^a   Ross, Ted ^c   Agadjanyan, Michael G ^a,b,d   Ghochikyan, Anahit ^a   Cribbs, David H ^b,e  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-11]; AMYLOID PRECURSOR PROTEIN; DNA EPITOPE VACCINE; DNA VACCINE; EPITOPE; P3ABETA1-11 PADRE 3C3D; PADRE EPITOPE; PLASMID DNA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; HAPLOTYPE; MOUSE; NEUROPATHOLOGY; NONHUMAN; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODY FORMATION; COMPLEMENT C3D; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; VACCINES, DNA;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 78649380771     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.219     Document Type: Article

References (66)

1. Agadjanyan, M.G., Ghochikyan, A., Petrushina, I., Vasilevko, V., Movsesyan, N., Mkrtichyan, M., Saing, T., and Cribbs, D.H. (2005). Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174, 1580-1586.
2. Ahearn, J.M., Fischer, M.B., Croix, D., Goerg, S., Ma, M., Xia, J., Zhou, X., Howard, R.G., Rothstein, T.L., and Carroll, M.C. (1996). Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4, 251-262.
3. Alexander, J., del Guercio, M.F., Maewal, A., Qiao, L., Fikes, J., Chesnut, R.W., Paulson, J., Bundle, D.R., DeFrees, S., and Sette, A. (2000). Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. 164, 1625-1633.
4. Babiuk, S., Baca-Estrada, M.E., Foldvari, M., Storms, M., Ra-bussay, D., Widera, G., and Babiuk, L.A. (2002). Electropora-tion improves the efficacy of DNA vaccines in large animals. Vaccine 20, 3399-3408.
5. Bard, F., Cannon, C., Barbour, R., Burke, R.L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., and Yednock, T. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919.
6. Bayer, A.J., Bullock, R., Jones, R.W., Wilkinson, D., Paterson, K.R., Jenkins, L., Millais, S.B., and Donoghue, S. (2005). Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64, 94-101.
7. Boche, D., DeBeer, S., Cox, A., Wilkinson, D., Holmes, C., Neal, J., Love, S., Esiri, M., Bridges, L., Weller, R., and Nicoll, J.A. (2007). Evidence of a transient increase in cerebral amyloid angiopathy after Abeta42 immunization in human Alzheimer's disease. In 8th International Conference "Alzheimer's and Parkinson's Disease: Progress and New Perspectives" (Salzburg, Austria).
8. Boyer, J.D., Chattergoon, M.A., Ugen, K.E., Shah, A., Bennett, M., Cohen, A., Nyland, S., Lacy, K.E., Bagarazzi, M.L., Higgins, T.J., Baine, Y., Ciccarelli, R.B., Ginsberg, R.S., Mac-Gregor, R.R., and Weiner, D.B. (1999). Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Clin. Immunol. 90, 100-107.
9. Boyer, J.D., Cohen, A.D., Vogt, S., Schumann, K., Nath, B., Ahn, L., Lacy, K., Bagarazzi, M.L., Higgins, T.J., Baine, Y., Ciccarelli, R.B., Ginsberg, R.S., MacGregor, R.R., and Weiner, D.B. (2000).
10. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J. Infect. Dis. 181, 476-483.
11. Carroll, M.C. (1998). The role of complement and complement receptors in induction and regulation of immunity. Annu. Rev. Immunol. 16, 545-568.
12. Carter, R.H., and Fearon, D.T. (1992). CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256, 105-107.
13. Cherukuri, A., Cheng, P.C., and Pierce, S.K. (2001). The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J. Immunol. 167, 163-172.
14. Conry, R.M., Curiel, D.T., Strong, T.V., Moore, S.E., Allen, K.O., Barlow, D.L., Shaw, D.R., and LoBuglio, A.F. (2002). Safety and immunogenicity of a DNA vaccine encoding carcinoem-bryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8, 2782-2787.
15. Cribbs, D.H., and Agadjanyan, M.G. (2005). Immunotherapy for Alzheimer's disease: potential problems and possible solutions. Curr. Immunol. Rev. 1, 139-155.
16. Cribbs, D.H., Ghochikyan, A., Vasilevko, V., Tran, M., Pet-rushina, I., Sadzikava, N., Babikyan, D., Kesslak, P., Kieber-Emmons, T., Cotman, C.W., and Agadjanyan, M.G. (2003). Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 15, 505-514.
17. Croix, D.A., Ahearn, J.M., Rosengard, A.M., Han, S., Kelsoe, G., Ma, M., and Carroll, M.C. (1996). Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J. Exp. Med. 183, 1857-1864.
18. Dempsey, P.W., Allison, M.E., Akkaraju, S., Goodnow, C.C., and Fearon, D.T. (1996). C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348-350.
19. Dodart, J.C., Bales, K.R., Gannon, K.S., Greene, S.J., DeMattos, R.B., Mathis, C., DeLong, C.A., Wu, S., Wu, X., Holtzman, D.M., and Paul, S.M. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5, 452-457.
20. Donnelly, J.J., and Ulmer, J.B. (1999). DNA vaccines for viral diseases. Braz. J. Med. Biol. Res. 32, 215-222.
21. Epstein, J.E., Charoenvit, Y., Kester, K.E., Wang, R., Newcomer, R., Fitzpatrick, S., Richie, T.L., Tornieporth, N., Heppner, D.G., Ockenhouse, C., Majam, V., Holland, C., Abot, E., Ganeshan, H., Berzins, M., Jones, T., Freydberg, C.N., Ng, J., Norman, J., Carucci, D.J., Cohen, J., and Hoffman, S.L. (2004). Safety, tol-erability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 22, 1592-1603. (Pubitemid 38447205)
22. Fearon, D.T., and Carroll, M.C. (2000). Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/ CD21 complex. Annu. Rev. Immunol. 18, 393-422.
23. Ferrer, I., Rovira, M.B., Guerra, M.L.S., Rey, M.J., and Costa-Jussa, F. (2004). Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14, 11-20.
24. Finkelman, F.D., Holmes, J., Katona I.M., Urban, J.F., Beckmann, M.P., Park, L.S., Schooley, K.A., Coffman, R.L., Mossmann, T.R., and Paul, W.E. (1990). Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8, 303-333.
25. Fynan, E.F., Webster, R.G., Fuller, D.H., Haynes, J.R., Santoro, J.C., and Robinson, H.L. (1993). DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U.S.A., 90, 11478-11482.
26. Ghochikyan, A., Vasilevko, V., Petrushina, I., Tran, M., Sadzi-kava, N., Babikyan, D., Movsesyan, N., Tian, W., Ross, T.M., Cribbs, D.H., and Agadjanyan, M.G. (2003). Generation and characterization of the humoral immune response to DNA immunization with a chimeric b-amyloid-interleukin-4 mini-gene. Eur. J. Immunol. 33, 3232-3241.
27. Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Rovira, M.B., Forette, F., and Or-gogozo, J.M. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562.
28. Haass, C., and Selkoe, D.J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8, 101-112.
29. Hardy, J.A., and Higgins, G.A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
30. Hasbold, J., Hong, J.S., Kehry, M.R., and Hodgkin, P.D. (1999). Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a. J. Immunol. 163, 4175-4181.
31. Hock, C., Konietzko, U., Streffer, J.R., Tracy, J., Signorell, A., Mü ller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., Wollmer, M.A., Umbricht, D., de Quervain, D.J., Hofmann, M., Maddalena, A., Papassotiropoulos, A., and Nitsch, R.M. (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554.
32. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R.W., Bullock, R., Love, S., Neal, J.W., Zotova, E., and Nicoll, J.A. (2008). Long-term effects of Abe-ta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223.
33. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996). Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
34. Janus, C., Pearson, J., McLaurin, J., Mathews, P.M., Jiang, Y., Schmidt, S.D., Chishti, M.A., Horne, P., Heslin, D., French, J., Mount, H.T., Nixon, R.A., Mercken, M., Bergeron, C., Fraser, P.E., St George-Hyslop, P., and Westaway, D. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
35. Kawarabayashi, T., Younkin, L.H., Saido, T.C., Shoji, M., Ashe, K.H., and Younkin, S.G. (2001). Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381.
36. Le, T.P., Coonan, K.M., Hedstrom, R.C., Charoenvit, Y., Sede-gah, M., Epstein, J.E., Kumar, S., Wang, R., Doolan, D.L., Maguire, J.D., Parker, S.E., Hobart, P., Norman, J., and Hoffman, S.L. (2000). Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18, 1893-1901.
37. Luxembourg, A., Evans, C.F., and Hannaman, D. (2007). Elec-troporation-based DNA immunisation: translation to the clinic. Expert Opin. Biol. Ther. 7, 1647-1664.
38. MacGregor, R.R., Boyer, J.D., Ugen, K.E., Lacy, K.E., Gluckman, S.J., Bagarazzi, M.L., Chattergoon, M.A., Baine, Y., Higgins, T.J., Ciccarelli, R.B., Coney, L.R., Ginsberg, R.S., and Weiner, D.B. (1998). First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178, 92-100.
39. Mamikonyan, G., Necula, M., Mkrtichyan, M., Ghochikyan, A., Petrushina, I., Movsesyan, N., Mina, E., Kiyatkin, A., Glabe, C., Cribbs, D.H., and Agadjanyan, M.G. (2007). Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J. Biol. Chem. 282, 22376-22386.
40. Masliah, E., Hansen, L., Adame, A., Crews, L., Bard, F., Lee, C., Seubert, P., Games, D., Kirby, L., and Schenk, D. (2005a). Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131.
41. Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., Games, D., and Schenk, D. (2005b). Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857-868.
42. Miller, A.M., Ozenci, V., Kiessling, R., and Pisa, P. (2005). Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J. Immu-nother. 28, 389-395.
43. Mitchell, J.A., Green, T.D., Bright, R.A., and Ross, T.M. (2003). Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21, 902-914.
44. Mongini, P.K., Vilensky, M.A., Highet, P.F., and Inman, J.K. (1997). The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J. Immunol. 159, 3782-3791.
45. Monsonego, A., Maron, R., Zota, V., Selkoe, D.J., and Weiner, H.L. (2001). Immune hyporesponsivness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Nat. Acad. Sci. U.S.A. 98, 10273-10278.
46. Morgan, D., Diamond, D.M., Gottschall, P.E., Ugen, K.E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., and Arendash, G.W. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
47. Movsesyan, N., Ghochikyan, A., Mkrtichyan, M., Petrushina, I., Davtyan, H., Olkhanud, P.B., Head, E., Biragyn, A., Cribbs, D.H., and Agadjanyan, M.G. (2008a). Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine- a novel immunotherapeutic strategy. PLoS One 3, e21-e24.
48. Movsesyan, N., Mkrtichyan, M., Petrushina, I., Ross, T.M., Cribbs, D.H., Agadjanyan, M.G., and Ghochikyan, A. (2008b). DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J. Neu-roimmunol. 205, 57-63.
49. Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., and Weller, R.O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448-452.
50. Nicoll, J.A., Barton, E., Boche, D., Neal, J.W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., Seubert, P., Schenk, D., and Holmes, C. (2006). Abeta species removal after Abeta42 immunization. J. Neuropathol. Exp. Neurol. 65, 1040-1048.
51. Nitsch, R.M., and Hock, C. (2007). Immunotherapy against beta-amyloid in Alzheimer's disease. In 8th International Conference "Alzheimer's and Parkinson's Disease: Progress and New Perspectives" (Salzburg, Austria).
52. Orgogozo, J.M., Gilman, S., Dartigues, J.M., Laurent, B., Puel, M., Kirby, L.C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., Michel, B.F., Boada, M., Frank, A., and Hock, C. (2003). Sub-acute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1), 46-54.
53. Otten, G., Schaefer, M., Doe, B., Liu, H., Srivastava, I., zur Me-gede, J., O'Hagan, D., Donnelly, J., Widera, G., Rabussay, D., Lewis, M.G., Barnett, S., and Ulmer, J.B. (2004). Enhancement of DNA vaccine potency in rhesus macaques by electropora-tion. Vaccine 22, 2489-2493.
54. Patton, R.L., Kalback, W.M., Esh, C.L., Kokjohn, T.A., Van Vickle, G.D., Luehrs, D.C., Kuo, Y.M., Lopez, J., Brune, D., Ferrer, I., Masliah, E., Newel, A.J., Beach, T.G., Castano, E.M., and Roher, A.E. (2006). Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 169, 1048-1063.
55. Petrushina, I., Tran, M., Sadzikava, N., Ghochikyan, A., Vasilevko, V., Agadjanyan, M.G., and Cribbs, D.H. (2003). Importance of IgG2c isotype in the immune response to beta-amyloid in APP/Tg mice. Neurosci. Lett. 338, 5-8.
56. Petrushina, I., Ghochikyan, A., Mktrichyan, M., Mamikonyan, G., Movsesyan, N., Davtyan, H., Patel, A., Head, E., Cribbs, D.H., and Agadjanyan, M.G. (2007). Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/ oligomeric A{beta} species in amyloid precursor protein transgenic mice. J. Neurosci. 27, 12721-12731.
57. Powell, K. (2004). DNA vaccines-back in the saddle again? Nat. Biotechnol. 22, 799-801.
58. Robinson, H.L., Hunt, L.A., and Webster, R.G. (1993). Protection against a lethal influenza virus challenge by immunization with a haemagglutinin- expressing plasmid DNA. Vaccine 11, 957-960.
59. Ross, T.M., Xu, Y., Bright, R.A., and Robinson, H.L. (2000). C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. [Comment in: Nat. Immunol. 2000 Aug;1(2):102-103]. Nat. Immunol. 1, 127-131.
60. Ross, T.M., Xu, Y., Green, T.D., Montefiori, D.C., and Robinson, H.L. (2001). Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res. Hum. Retroviruses 17, 829-835.
61. Rottinghaus, S.T., Poland, G.A., Jacobson, R.M., Barr, L.J., and Roy, M.J. (2003). Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21, 4604-4608.
62. Scheerlinck, J.P., Karlis, J., Tjelle, T.E., Presidente, P.J., Mathie-sen, I., and Newton, S.E. (2004). In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 22, 1820-1825.
63. Schenk, D. (2002). Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824-828.
64. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature 400, 173-177.
65. Snapper, C.M., and Paul, W.E. (1987). Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236, 944-947.
66. Tong, T., Fan, H., Tan, Y., Xiao, S., Ling, J., Chen, H., and Guo, A. (2006). C3d enhanced DNA vaccination induced humoral immune response to glycoprotein C of pseudorabies virus. Biochem. Biophys. Res. Commun. 347, 845-851.